POLE and neoplasm: Given the increasing role of tumor DNA repair deficiency as a predictive clinical biomarker—including the role of MSI and POLE/POLD1 mutations as predictors of response to immune checkpoint blockade27–29—a deeper understanding of the mutational processes in these tumors may ultimately inform clinical decision-making.